Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Alan Pollack
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Procedures
Concepts & Ideas
Anatomy
Sign-in to see full Profile
Network (preview)
73
Zagars, Gunar
43
Horwitz, Eric
31
Hanlon, Alexandra
28
Uzzo, Robert
27
von Eschenbach, Andrew
22
Buyyounouski, Mark K.
19
Roach, Mack
17
Feigenberg, Steven
15
Irvin, George
14
Block, Norman
13
Hanks, Gerald
13
Kuban, Deborah
13
Terry, Nicholas
13
Shipley, William
13
Meistrich, Marvin
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Alan Pollack (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Pollack Alan; Bae Kyounghwa; Khor Li-Yan; Al-Saleem Tahseen; Hammond M Elizabeth; Venkatesan Varagur; Byhardt Roger W; Asbell Sucha O; Shipley William U; Sandler Howard M
The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(17):5478-84.
-
2009: Roach Mack; Waldman Fred; Pollack Alan
Predictive models in external beam radiotherapy for clinically localized prostate cancer.
Cancer 2009;115(13 Suppl):3112-20.
-
2009: Khor Li-Yan; Bae Kyounghwa; Paulus Rebecca; Al-Saleem Tahseen; Hammond M Elizabeth; Grignon David J; Che Mingxin; Venkatesan Varagur; Byhardt Roger W; Rotman Marvin; Hanks Gerald E; Sandler Howard M; Pollack Alan
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3177-84.
-
2009: Michalski Jeff M; Roach Mack; Merrick Gregory; Anscher Mitchell S; Beyer David C; Lawton Colleen A; Lee W Robert; Pollack Alan; Rosenthal Seth A; Vijayakumar Srinivasan; Carroll Peter R
ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate.
International journal of radiation oncology, biology, physics 2009;74(3):667-72.
-
2009: Zhang Min; Ho Alex; Hammond Elizabeth H; Suzuki Yoshiyuki; Bermudez R Scott; Lee R Jeffrey; Pilepich Michael; Shipley William U; Sandler Howard; Khor Li-Yan; Pollack Alan; Chakravarti Arnab
Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.
International journal of radiation oncology, biology, physics 2009;73(4):1033-42.
-
2009: Konski Andre; Movsas Benjamin; Konopka Maryann; Ma Charlie; Price Robert; Pollack Alan
Developing a radiation error scoring system to monitor quality control events in a radiation oncology department.
Journal of the American College of Radiology : JACR 2009;6(1):45-50.
-
2008: Trabulsi Edouard J; Valicenti Richard K; Hanlon Alexandra L; Pisansky Thomas M; Sandler Howard M; Kuban Deborah A; Catton Charles N; Michalski Jeff M; Zelefsky Michael J; Kupelian Patrick A; Lin Daniel W; Anscher Mitchell S; Slawin Kevin M; Roehrborn Claus G; Forman Jeffrey D; Liauw Stanley L; Kestin Larry L; DeWeese Theodore L; Scardino Peter T; Stephenson Andrew J; Pollack Alan
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.
Urology 2008;72(6):1298-302; discussion 1302-4.
-
2008: D'Ambrosio David J; Li Tianyu; Horwitz Eric M; Chen David Y T; Pollack Alan; Buyyounouski Mark K
Does treatment duration affect outcome after radiotherapy for prostate cancer?
International journal of radiation oncology, biology, physics 2008;72(5):1402-7.
-
2008: Udayakumar Thirupandiyur S; Hachem Paul; Ahmed Mansoor M; Agrawal Sudhir; Pollack Alan
Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.
Molecular cancer research : MCR 2008;6(11):1742-54.
-
2008: Khor Li-Yan; Bae Kyounghwa; Al-Saleem Tahseen; Hammond Elizabeth H; Grignon David J; Sause William T; Pilepich Miljenko V; Okunieff Paul P; Sandler Howard M; Pollack Alan
Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10.
International journal of radiation oncology, biology, physics 2008;71(5):1309-15.
-
2008: Eade Thomas N; Horwitz Eric M; Ruth Karen; Buyyounouski Mark K; D'Ambrosio David J; Feigenberg Steven J; Chen David Y T; Pollack Alan
A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant.
International journal of radiation oncology, biology, physics 2008;71(2):338-45.
-
2008: D'Ambrosio David J; Ruth Karen; Horwitz Eric M; Chen David Y T; Pollack Alan; Buyyounouski Mark K
Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
Urology 2008;71(5):938-41.
-
2008: Mu Zhaomei; Hachem Paul; Hensley Harvey; Stoyanova Radka; Kwon Hae Won; Hanlon Alexandra L; Agrawal Sudhir; Pollack Alan
Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
The Prostate 2008;68(6):599-609.
-
2008: D'Ambrosio David J; Ruth Karen; Horwitz Eric M; Uzzo Robert G; Pollack Alan; Buyyounouski Mark K
How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
International journal of radiation oncology, biology, physics 2008;70(5):1487-91.
-
2008: Diefenbach Michael; Mohamed Nihal Elamin; Horwitz Eric; Pollack Alan
Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: the moderating role of age.
Psychology, health & medicine 2008;13(2):146-61.
-
2008: D'Ambrosio David J; Pollack Alan; Harris Eleanor E R; Price Robert A; Verhey Lynn J; Roach Mack; Demanes D Jeffrey; Steinberg Michael L; Potters Louis; Wallner Paul E; Konski Andre
Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer.
International journal of radiation oncology, biology, physics 2008;70(3):671-7.
-
2008: Abramowitz Matthew C; Pollack Alan
Postprostatectomy radiation therapy for prostate cancer.
Seminars in radiation oncology 2008;18(1):15-22.
-
2008: Abramowitz Matthew C; Li Tiaynu; Buyyounouski Mark K; Ross Eric; Uzzo Robert G; Pollack Alan; Horwitz Eric M
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer.
Cancer 2008;112(1):55-60.
-
2008: Buyyounouski Mark K; Hanlon Alexandra L; Horwitz Eric M; Pollack Alan
Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.
International journal of radiation oncology, biology, physics 2008;70(1):59-66.
-
2008: Kuban Deborah A; Tucker Susan L; Dong Lei; Starkschall George; Huang Eugene H; Cheung M Rex; Lee Andrew K; Pollack Alan
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.
International journal of radiation oncology, biology, physics 2008;70(1):67-74.
-
2007: Che Mingxin; DeSilvio Michelle; Pollack Alan; Grignon David J; Venkatesan Varagur Mohan; Hanks Gerald E; Sandler Howard M;
Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.
International journal of radiation oncology, biology, physics 2007;69(4):1117-23.
-
2007: Khor Li-Yan; Bae Kyounghwa; Pollack Alan; Hammond M Elizabeth H; Grignon David J; Venkatesan Varagur M; Rosenthal Seth A; Ritter Mark A; Sandler Howard M; Hanks Gerald E; Shipley William U; Dicker Adam P
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
The lancet oncology 2007;8(10):912-20.
-
2007: Roach Mack; De Silvio Michelle; Rebbick Timothy; Grignon David; Rotman Marvin; Wolkov Harvey; Fisher Barbara; Hanks Gerald; Shipley William U; Pollack Alan; Sandler Howard; Watkins-Bruner Deborah
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.
International journal of radiation oncology, biology, physics 2007;69(1):79-87.
-
2007: Konski Andre; Speier William; Hanlon Alexandra; Beck J Robert; Pollack Alan
Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3603-8.
-
2007: Kawachi Mark H; Bahnson Robert R; Barry Michael; Carroll Peter R; Carter H Ballentine; Catalona William J; Epstein Jonathan I; Etzioni Ruth B; Hemstreet George P; Howe Richard J; Kopin Jeff D; Lange Paul H; Lilja Hans; Mohler James; Moul Judd; Nadler Robert B; Patterson Stephan; Pollack Alan; Presti Joseph C; Stroup Antoinette M; Urban Donald A; Wake Robert; Wei John T;
Prostate cancer early detection. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(7):714-36.
-
2007: Mohler James; Babaian Richard J; Bahnson Robert R; Boston Barry; D'Amico Anthony; Eastham James A; Hauke Ralph J; Huben Robert P; Kantoff Philip; Kawachi Mark; Kuettel Michael; Lange Paul H; Logothetis Chris; MacVicar Gary; Pollack Alan; Pow-Sang Julio M; Roach Mack; Sandler Howard; Shrieve Dennis; Srinivas Sandhya; Twardowski Przemyslaw; Urban Donald A; Walsh Patrick C;
Prostate cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(7):650-83.
-
2007: Feng Mary; Hanlon Alexandra L; Pisansky Thomas M; Kuban Deborah; Catton Charles N; Michalski Jeff M; Zelefsky Michael J; Kupelian Patrick A; Pollack Alan; Kestin Larry L; Valicenti Richard K; DeWeese Theodore L; Sandler Howard M
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy.
International journal of radiation oncology, biology, physics 2007;68(5):1417-23.
-
2007: Stoyanova Radka; Hachem Paul; Hensley Harvey; Khor Li-Yan; Mu Zhaomei; Hammond M Elizabeth H; Agrawal Sudhir; Pollack Alan
Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.
International journal of radiation oncology, biology, physics 2007;68(4):1151-60.
-
2007: Chakravarti Arnab; DeSilvio Michelle; Zhang Min; Grignon David; Rosenthal Seth; Asbell Sucha O; Hanks Gerald; Sandler Howard M; Khor Li-Yan; Pollack Alan; Shipley William;
Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3082-9.
-
2007: Chen Lili; Nguyen Thai-Binh; Jones Elan; Chen Zuoqun; Luo Wei; Wang Lu; Price Robert A; Pollack Alan; Ma C-M Charlie
Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographs.
International journal of radiation oncology, biology, physics 2007;68(3):903-11.
-
2007: Morgan Peter B; Hanlon Alexandra L; Horwitz Eric M; Buyyounouski Mark K; Uzzo Robert G; Pollack Alan
Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy.
Cancer 2007;110(1):68-80.
-
2007: Eade Thomas N; Hanlon Alexandra L; Horwitz Eric M; Buyyounouski Mark K; Hanks Gerald E; Pollack Alan
What dose of external-beam radiation is high enough for prostate cancer?
International journal of radiation oncology, biology, physics 2007;68(3):682-9.
-
2007: Khor Li Yan; Moughan Jennifer; Al-Saleem Tahseen; Hammond Elizabeth H; Venkatesan Varagur; Rosenthal Seth A; Ritter Mark A; Sandler Howard M; Hanks Gerald E; Shipley William U; Pollack Alan
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3585-90.
-
2007: Stephenson Andrew J; Scardino Peter T; Kattan Michael W; Pisansky Thomas M; Slawin Kevin M; Klein Eric A; Anscher Mitchell S; Michalski Jeff M; Sandler Howard M; Lin Daniel W; Forman Jeffrey D; Zelefsky Michael J; Kestin Larry L; Roehrborn Claus G; Catton Charles N; DeWeese Theodore L; Liauw Stanley L; Valicenti Richard K; Kuban Deborah A; Pollack Alan
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2035-41.
-
2007: Eade Thomas N; Al-Saleem Tahseen; Horwitz Eric M; Buyyounouski Mark K; Chen David Y T; Pollack Alan
Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate.
Cancer 2007;109(10):2011-5.
-
2007: Crispen Paul L; Uzzo Robert G; Golovine Konstantin; Makhov Peter; Pollack Alan; Horwitz Eric M; Greenberg Richard E; Kolenko Vladimir M
Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention.
The Prostate 2007;67(6):582-90.
-
2007: Torres-Roca Javier F; DeSilvio Michelle; Mora Linda B; Khor Li Yan; Hammond Elizabeth; Ahmad Nazeel; Jove Richard; Forman Jeffrey; Lee R Jeffrey; Sandler Howard; Pollack Alan
Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10.
Urology 2007;69(3):505-9.
-
2007: Pisansky Thomas M; Pollack Alan; Sandler Howard M; Valicenti Richard K
Advanced prostate cancer and postoperative radiotherapy.
JAMA : the journal of the American Medical Association 2007;297(9):950-1; author reply 951.
-
2007: D'Ambrosio David J; Hanlon Alexandra L; Al-Saleem Tahseen; Feigenberg Steven J; Horwitz Eric M; Uzzo Robert G; Pollack Alan; Buyyounouski Mark K
The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.
International journal of radiation oncology, biology, physics 2007;67(4):1082-7.
-
2007: Morgan Peter B; Hanlon Alexandra L; Horwitz Eric M; Buyyounouski Mark K; Uzzo Robert G; Pollack Alan
Radiation dose and late failures in prostate cancer.
International journal of radiation oncology, biology, physics 2007;67(4):1074-81.
-
2007: Alcantara Pino; Hanlon Alexandra; Buyyounouski Mark K; Horwitz Eric M; Pollack Alan
Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.
Cancer 2007;109(1):41-7.
-
2007: Feigenberg Steven J; Paskalev Kamen; McNeeley Shawn; Horwitz Eric M; Konski Andre; Wang Lu; Ma Charlie; Pollack Alan
Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluation.
Journal of applied clinical medical physics / American College of Medical Physics 2007;8(3):2268.
-
2006: Montie James E; Abrahams Neil A; Bahnson Robert R; Eisenberger Mario A; El-Galley Rizk; Herr Harry W; Hudes Gary R; Kuzel Timothy M; Lange Paul H; Patterson Anthony; Pollack Alan; Richie Jerome P; Sexton Wade J; Shipley William U; Small Eric J; Trump Donald L; Walther Phillip J; Wilson Timothy G;
Bladder cancer. Clinical guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(10):984-1014.
-
2006: Feigenberg Steven J; Hanlon Alexandra L; Horwitz Eric M; Uzzo Robert G; Eisenberg Debra; Pollack Alan
A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
American journal of clinical oncology 2006;29(5):458-62.
-
2006: Price Robert A; Hannoun-Levi Jean-Michel; Horwitz Eric; Buyyounouski Mark; Ruth Karen J; Ma C-M; Pollack Alan
Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer.
International journal of radiation oncology, biology, physics 2006;66(2):583-92.
-
2006: Konski Andre; Watkins-Bruner Deborah; Feigenberg Steven; Hanlon Alexandra; Kulkarni Sachin; Beck J Robert; Horwitz Eric M; Pollack Alan
Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.
International journal of radiation oncology, biology, physics 2006;66(2):408-15.
-
2006: Khor Li-Yan; Desilvio Michelle; Li Rile; McDonnell Timothy J; Hammond M Elizabeth H; Sause William T; Pilepich Miljenko V; Okunieff Paul; Sandler Howard M; Pollack Alan
Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.
International journal of radiation oncology, biology, physics 2006;66(1):25-30.
-
2006: Konski Andre; Eisenberg Debra; Horwitz Eric; Hanlon Alexandra; Pollack Alan; Hanks Gerald
Does age matter in the selection of treatment for men with early-stage prostate cancer?
Cancer 2006;106(12):2598-602.
-
2006: Pickles Tom; Pollack Alan
The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer.
The Canadian journal of urology 2006;13 Suppl 2():68-71.
-
2006: Abdel-Wahab May; Berkey Brian A; Krishan Awtar; O'Brien Tom; Hammond Elizabeth; Roach Mack; Lawton Colleen; Pilepich Milijenko; Markoe Arnold; Pollack Alan
Influence of number of CAG repeats on local control in the RTOG 86-10 protocol.
American journal of clinical oncology 2006;29(1):14-20.
-
2006: Pollack Alan; Hanlon Alexandra L; Horwitz Eric M; Feigenberg Steven J; Konski Andre A; Movsas Benjamin; Greenberg Richard E; Uzzo Robert G; Ma C-M Charlie; McNeeley Shawn W; Buyyounouski Mark K; Price Robert A
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.
International journal of radiation oncology, biology, physics 2006;64(2):518-26.
-
2005: Buyyounouski Mark K; Hanlon Alexandra L; Eisenberg Debra F; Horwitz Eric M; Feigenberg Steven J; Uzzo Robert G; Pollack Alan
Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
International journal of radiation oncology, biology, physics 2005;63(5):1455-62.
-
2005: Mu Zhaomei; Hachem Paul; Pollack Alan
Antisense Bcl-2 sensitizes prostate cancer cells to radiation.
The Prostate 2005;65(4):331-40.
-
2005: Hayes Shelly Bowers; Pollack Alan
Parameters for treatment decisions for salvage radiation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(32):8204-11.
-
2005: Khor Li-Yan; Desilvio Michelle; Al-Saleem Tahseen; Hammond M Elizabeth; Grignon David J; Sause William; Pilepich Michael; Okunieff Paul; Sandler Howard; Pollack Alan;
MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.
Cancer 2005;104(5):962-7.
-
2005: Nguyen Khanh H; Hachem Paul; Khor Li-Yan; Salem Naji; Hunt Kelly K; Calkins Peter R; Pollack Alan
Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.
International journal of radiation oncology, biology, physics 2005;63(1):238-46.
-
2005: Andrews Stephen F; Horwitz Eric M; Feigenberg Steven J; Eisenberg Debra F; Hanlon Alexandra L; Uzzo Robert G; Pollack Alan
Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
Cancer 2005;104(2):299-304.
-
2005: Feigenberg Steven J; Hanlon Alexandra L; Horwitz Eric M; Uzzo Robert G; Eisenberg Debra; Pollack Alan
Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.
International journal of radiation oncology, biology, physics 2005;62(2):397-405.
-
2005: Chakravarti Arnab; Winter Kathryn; Wu Chin-Lee; Kaufman Donald; Hammond Elizabeth; Parliament Matthew; Tester William; Hagan Michael; Grignon David; Heney Niall; Pollack Alan; Sandler Howard; Shipley William
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
International journal of radiation oncology, biology, physics 2005;62(2):309-17.
-
2005: Buyyounouski Mark K; Hanlon Alexandra L; Horwitz Eric M; Uzzo Robert G; Pollack Alan
Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
International journal of radiation oncology, biology, physics 2005;61(5):1291-8.
-
2005: Chertin B; Rabinowitz R; Pollack A; Koulikov D; Fridmans A; Hadas-Halpern I; Farkas A
Does prenatal diagnosis influence the morbidity associated with left in situ nonfunctioning or poorly functioning renal moiety after endoscopic puncture of ureterocele?
The Journal of urology 2005;173(4):1349-52.
-
2005: Feigenberg Steven J; Hanlon Alexandra L; Horwitz Eric M; Uzzo Robert G; Eisenberg Debra F; Pollack Alan
What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
International journal of radiation oncology, biology, physics 2005;61(4):1003-10.
-
2005: Jacob Rojymon; Hanlon Alexandra L; Horwitz Eric M; Movsas Benjamin; Uzzo Robert G; Pollack Alan
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement.
International journal of radiation oncology, biology, physics 2005;61(3):695-701.
-
2005: Pollack Alan; Horwitz Eric M
Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
Nature clinical practice. Oncology 2005;2(1):12-3.
-
2005: Paskalev Kamen; Feigenberg Steven; Jacob Rojymon; McNeeley Shawn; Horwitz Eric; Price Robert; Ma Charlie; Pollack Alan
Target localization for post-prostatectomy patients using CT and ultrasound image guidance.
Journal of applied clinical medical physics / American College of Medical Physics 2005;6(4):40-9.
-
2004: Buyyounouski Mark K; Hanlon Alexandra L; Price Robert A; Horwitz Eric M; Feigenberg Steven J; Pollack Alan
In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046.
International journal of radiation oncology, biology, physics 2004;60(5):1664-5; author reply 1666.
-
2004: Chen L; Price R A; Nguyen T-B; Wang L; Li J S; Qin L; Ding M; Palacio E; Ma C-M; Pollack A
Dosimetric evaluation of MRI-based treatment planning for prostate cancer.
Physics in medicine and biology 2004;49(22):5157-70.
-
2004: Horwitz Eric M; Feigenberg Steven J; Pollack Alan; Hanks Gerald E; Uzzo Robert G
Androgen suppression plus radiation therapy for prostate cancer.
JAMA : the journal of the American Medical Association 2004;292(17):2084-5; author reply 2085.
-
2004: Chen Lili; Price Robert A; Wang Lu; Li Jinsheng; Qin Lihong; McNeeley Shawn; Ma C-M Charlie; Freedman Gary M; Pollack Alan
MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT.
International journal of radiation oncology, biology, physics 2004;60(2):636-47.
-
2004: Buyyounouski Mark K; Horwitz Eric M; Uzzo Robert G; Price Robert A; McNeeley Shawn W; Azizi Daniel; Hanlon Alexandra L; Milestone Bart N; Pollack Alan
The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
International journal of radiation oncology, biology, physics 2004;59(5):1383-91.
-
2004: Mu Zhaomei; Hachem Paul; Agrawal Sudhir; Pollack Alan
Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
The Prostate 2004;60(3):187-96.
-
2004: Li Rile; Heydon Kateri; Hammond M Elizabeth; Grignon David J; Roach Mack; Wolkov Harvey B; Sandler Howard M; Shipley William U; Pollack Alan
Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4118-24.
-
2004: Pollack A; DeSilvio M; Khor L-Y; Li R; Al-Saleem T I; Hammond M E; Venkatesan V; Lawton C A; Roach M; Shipley W U; Hanks G E; Sandler H M
Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2133-40.
-
2004: Andrews Stephen F; Anderson Penny R; Eisenberg Burton L; Hanlon Alexandra L; Pollack Alan
Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy.
International journal of radiation oncology, biology, physics 2004;59(2):475-80.
-
2004: Chism Derek B; Hanlon Alexandra L; Horwitz Eric M; Feigenberg Steven J; Pollack Alan
A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy.
International journal of radiation oncology, biology, physics 2004;59(2):380-5.
-
2004: Li J S; Freedman G M; Price R; Wang L; Anderson P; Chen L; Xiong W; Yang J; Pollack A; Ma C M
Clinical implementation of intensity-modulated tangential beam irradiation for breast cancer.
Medical physics 2004;31(5):1023-31.
-
2004: Uzzo R G; Brown J G; Horwitz E M; Hanlon A; Mazzoni S; Konski A; Greenberg R E; Pollack A; Kolenko V; Watkins-Bruner D
Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer.
BJU international 2004;93(7):955-60.
-
2004: Paskalev K; Ma C M; Jacob R; Price R; McNeeley S; Wang L; Movsas B; Pollack A
Daily target localization for prostate patients based on 3D image correlation.
Physics in medicine and biology 2004;49(6):931-9.
-
2004: Buyyounouski Mark K; Horwitz Eric M; Price Robert A; Hanlon Alexandra L; Uzzo Robert G; Pollack Alan
Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment.
International journal of radiation oncology, biology, physics 2004;58(3):743-9.
-
2004: Buyyounouski Mark K; Horwitz Eric M; Hanlon Alexandra L; Uzzo Robert G; Pollack Alan
Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database.
The Journal of urology 2004;171(3):1246-7; author reply 1247.
-
2004: Pollack Alan; Hanlon Alexandra L; Horwitz Eric M; Feigenberg Steven J; Uzzo Robert G; Hanks Gerald E
Prostate cancer radiotherapy dose response: an update of the fox chase experience.
The Journal of urology 2004;171(3):1132-6.
-
2004: Mu Zhaomei; Hachem Paul; Agrawal Sudhir; Pollack Alan
Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination.
International journal of radiation oncology, biology, physics 2004;58(2):336-43.
-
2004: Jacob Rojymon; Hanlon Alexandra L; Horwitz Eric M; Movsas Benjamin; Uzzo Robert G; Pollack Alan
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.
Cancer 2004;100(3):538-43.
-
2004: Hanlon Alexandra L; Horwitz Eric M; Hanks Gerald E; Pollack Alan
Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer.
International journal of radiation oncology, biology, physics 2004;58(1):43-52.
-
2004: Bruner Deborah Watkins; Hanlon Alexandra; Mazzoni Susan; Raysor Susan; Konski Andre; Hanks Gerald; Pollack Alan
Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer.
International journal of radiation oncology, biology, physics 2004;58(1):34-42.
-
2004: Wang L; Movsas B; Jacob R; Fourkal E; Chen L; Price R; Feigenberg S; Konski A; Pollack A; Ma C
Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT.
Journal of applied clinical medical physics / American College of Medical Physics 2004;5(2):29-41.
-
2003: Kuban Deborah; Pollack Alan; Huang Eugene; Levy Larry; Dong Lei; Starkschall George; Rosen Isaac
Hazards of dose escalation in prostate cancer radiotherapy.
International journal of radiation oncology, biology, physics 2003;57(5):1260-8.
-
2003: Hensley Harvey; Pollack Alan
In vivo visualization of metastatic prostate cancer.
Cancer biology & therapy 2003;2(6):661-2.
-
2003: Price Robert A; Murphy Scott; McNeeley Shawn W; Ma C-M Charlie; Horwitz Eric; Movsas Benjamin; Raben Adam; Pollack Alan
A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate.
International journal of radiation oncology, biology, physics 2003;57(3):843-52.
-
2003: Little Darren J; Kuban Deborah A; Levy Lawrence B; Zagars Gunar K; Pollack Alan
Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study.
Urology 2003;62(4):707-13.
-
2003: Nguyen Khanh H; Horwitz Eric M; Hanlon Alexandra L; Uzzo Robert G; Pollack Alan
Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?
International journal of radiation oncology, biology, physics 2003;57(2):377-83.
-
2003: Lee Hoon K; D'Souza Warren D; Yamal Jose-Miguel J; Pollack Alan; Lee Andrew K; Palmer Matthew B; Kuban Deborah A
Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer.
International journal of radiation oncology, biology, physics 2003;57(2):355-61.
-
2003: Pollack Alan; Hanlon Alex; Horwitz Eric M; Feigenberg Steven; Uzzo Robert G; Price Robert A
Radiation therapy dose escalation for prostate cancer: a rationale for IMRT.
World journal of urology 2003;21(4):200-8.
-
2003: Chakravarti A; Heydon K; Wu C L; Hammond E; Pollack A; Roach M; Wolkov H; Okunieff P; Cox J; Fontanesi J; Abrams R; Pilepich M; Shipley W;
Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(17):3328-34.
-
2003: Kaminski Joseph M L; Hanlon Alexandra L; Joon Daryl Lim; Meistrich Marvin; Hachem Paul; Pollack Alan
Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth.
International journal of radiation oncology, biology, physics 2003;57(1):24-8.
-
2003: Pollack Alan; Hanlon Alexandra L; Movsas Benjamin; Hanks Gerald E; Uzzo Robert; Horwitz Eric M
Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy.
International journal of radiation oncology, biology, physics 2003;57(1):19-23.
-
2003: Theodorescu Dan; Pollack Alan
Radiation for prostate cancer issue.
World journal of urology 2003;21(4):189.
-
2003: Buyyounouski Mark K; Horwitz Eric M; Hanlon Alexandra L; Uzzo Robert G; Hanks Gerald E; Pollack Alan
Positive prostate biopsy laterality and implications for staging.
Urology 2003;62(2):298-303.
-
2003: Chism Derek B; Hanlon Alexandra L; Troncoso Patricia; Al-Saleem Tahseen; Horwitz Eric M; Pollack Alan
The Gleason score shift: score four and seven years ago.
International journal of radiation oncology, biology, physics 2003;56(5):1241-7.
-
2003: Diefenbach Michael A; Hamrick Natalie; Uzzo Robert; Pollack Alan; Horwitz Eric; Greenberg Richard; Engstrom Paul F
Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer.
The Journal of urology 2003;170(1):166-9.
-
2003: Taylor N; Kelly J F; Kuban D A; Babaian R J; Pisters L L; Pollack A
Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.
International journal of radiation oncology, biology, physics 2003;56(3):755-63.
-
2003: Rosser Charles J; Levy Lawrence B; Kuban Deborah A; Chichakli Ramsey; Pollack Alan; Lee Andrew; Pisters Louise L
Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate.
The Journal of urology 2003;169(6):2160-5.
-
2003: Horwitz Eric M; Uzzo Robert G; Hanlon Alexandra L; Greenberg Richard E; Hanks Gerald E; Pollack Alan
Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone.
The Journal of urology 2003;169(6):2153-7; discussion 2157-9.
-
2003: D'Souza Warren D; Lee Hoon K; Palmer Matthew B; Smith Lewis G; Pollack Alan
Is intraoperative nomogram-based overplanning of prostate implants necessary?
International journal of radiation oncology, biology, physics 2003;56(2):462-7.
-
2003: Chandra Anurag; Dong Lei; Huang Eugene; Kuban Deborah A; O'Neill Laura; Rosen Isaac; Pollack Alan
Experience of ultrasound-based daily prostate localization.
International journal of radiation oncology, biology, physics 2003;56(2):436-47.
-
2003: Pollack Alan
A call for more with a desire for less: pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10):1899-901.
-
2003: Pollack Alan; Horwitz Eric M; Movsas Benjamin; Hanlon Alexandra L
Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment.
The Urologic clinics of North America 2003;30(2):337-49, x.
-
2003: Michalski Jeff M; Winter Kathryn; Purdy James A; Wilder Richard B; Perez Carlos A; Roach Mack; Parliament Matthew B; Pollack Alan; Markoe Arnold M; Harms W; Sandler Howard M; Cox James D
Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
International journal of radiation oncology, biology, physics 2003;56(1):192-8.
-
2003: Pollack Alan; Horwitz Eric M; Movsas Ben
Treatment of prostate cancer with regional lymph node (N1) metastasis.
Seminars in radiation oncology 2003;13(2):121-9.
-
2003: Uzzo Robert G; Pinover Wayne H; Horwitz Eric M; Parlanti Alicia; Mazzoni Susan; Raysor Susan; Mirchandani Ila; Greenberg Richard E; Pollack Alan; Hanks Gerald E; Watkins-Bruner Deborah
Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Urology 2003;61(4):754-9.
-
2003: Pollack A; Grignon D J; Heydon K H; Hammond E H; Lawton C A; Mesic J B; Fu K K; Porter A T; Abrams R A; Shipley W U
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(7):1238-48.
-
2003: Pollack Alan; Cowen Didier; Troncoso Patricia; Zagars Gunar K; von Eschenbach Andrew C; Meistrich Marvin L; McDonnell Timothy
Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Cancer 2003;97(7):1630-8.
-
2002: Huang Eugene H; Pollack Alan; Levy Larry; Starkschall George; Dong Lei; Rosen Isaac; Kuban Deborah A
Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer.
International journal of radiation oncology, biology, physics 2002;54(5):1314-21.
-
2002: Ryu Janice K; Winter Kathryn; Michalski Jeff M; Purdy James A; Markoe Arnold M; Earle John D; Perez Carlos A; Roach Mack; Sandler Howard M; Pollack Alan; Cox James D
Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).
International journal of radiation oncology, biology, physics 2002;54(4):1036-46.
-
2002: Rosser Charles J; Kuban Deborah A; Levy Lawrence B; Chichakli Ramsey; Pollack Alan; Lee Andrew K; Pisters Louis L
Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer.
The Journal of urology 2002;168(5):2001-5.
-
2002: Pollack Alan; Zagars Gunar K; Antolak John A; Kuban Deborah A; Rosen Isaac I
Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.
International journal of radiation oncology, biology, physics 2002;54(3):677-85.
-
2002: Movsas Benjamin; Chapman J Donald; Hanlon Alexandra L; Horwitz Eric M; Greenberg Richard E; Stobbe Corinne; Hanks Gerald E; Pollack Alan
Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings.
Urology 2002;60(4):634-9.
-
2002: Pollack Alan; Kuban Deborah A; Zagars Gunar K
Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer.
Urology 2002;60(3 Suppl 1):22-30; discussion 30-1.
-
2002: Carroll Peter R; Kantoff Philip W; Balk Steven P; Brown Myles A; D'amico Anthony V; George Daniel J; Grossfeld Gary D; Johnson Candace S; Kelly William Kevin; Klotz Laurence; Lee W Robert; Lubeck Deborah P; Mcleod David G; Oh William K; Pollack Alan; Sartor Oliver; Smith Matthew R; Hart Carol;
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
Urology 2002;60(3 Suppl 1):1-6.
-
2002: Pollack Alan; Zagars Gunar K; Starkschall George; Antolak John A; Lee J Jack; Huang Eugene; von Eschenbach Andrew C; Kuban Deborah A; Rosen Isaac
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.
International journal of radiation oncology, biology, physics 2002;53(5):1097-105.
-
2002: Pollack Alan; Horwitz Eric M
In regard to Sherertz et al., IJROBP 2001; 51:1241-1245.
International journal of radiation oncology, biology, physics 2002;53(2):512; author reply 512.
-
2002: Huang Eugene; Dong Lei; Chandra Anurag; Kuban Deborah A; Rosen Isaac I; Evans Anissa; Pollack Alan
Intrafraction prostate motion during IMRT for prostate cancer.
International journal of radiation oncology, biology, physics 2002;53(2):261-8.
-
2002: Cowen Didier; Troncoso Patricia; Khoo Vincent S; Zagars Gunar K; von Eschenbach Andrew C; Meistrich Marvin L; Pollack Alan
Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1148-54.
-
2002: Kaminski J M; Nguyen K; Buyyounouski M; Pollack A
Prostate cancer gene therapy and the role of radiation.
Cancer treatment reviews 2002;28(1):49-64.
-
2002: Michalski Jeff M; Winter Kathryn; Purdy James A; Wilder Richard; Perez Carlos A; Roach Mack; Parliament Matthew; Pollack Allan; Markoe Arnold; Harms William B; Sandler Howard; Cox James D
Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406.
Seminars in radiation oncology 2002;12(1 Suppl 1):75-80.
-
2001: Pollack A; Salem N; Ashoori F; Hachem P; Sangha M; von Eschenbach A C; Meistrich M L
Lack of prostate cancer radiosensitization by androgen deprivation.
International journal of radiation oncology, biology, physics 2001;51(4):1002-7.
-
2001: Zagars G K; Pollack A
Radiotherapy for stage II testicular seminoma.
International journal of radiation oncology, biology, physics 2001;51(3):643-9.
-
2001: Zagars G K; Pollack A; von Eschenbach A C
Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.
Urology 2001;58(2):233-9.
-
2001: Goldie S J; Kuhn L; Denny L; Pollack A; Wright T C
Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
JAMA : the journal of the American Medical Association 2001;285(24):3107-15.
-
2001: Campbell T; Blasko J; Crawford E D; Forman J; Hanks G; Kuban D; Montie J; Moul J; Pollack A; Raghavan D; Ray P; Roach M; Steinberg G; Stone N; Thompson I; Vogelzang N; Vijayakumar S
Clinical staging of prostate cancer: reproducibility and clarification of issues.
International journal of cancer. Journal international du cancer 2001;96(3):198-209.
-
2001: Starkschall G; Pollack A; Stevens C W
Treatment planning using a dose-volume feasibility search algorithm.
International journal of radiation oncology, biology, physics 2001;49(5):1419-27.
-
2001: Okunieff P; Hammond E; Grignon D; Langer C; Pajak T F; Ang K; Bruner D W; Travis E; Greven K; Guha A; Moulder J; Pollack A; Scarantino C; Sneige N; Watson J; Amin M; Bondy M; Chakravarti A; Chapman J D; Dicker A; Harris J; Koch W; Komaki R; Lange C; McBride W; Mitchell J; Milas L; Movsas B; Pandya K; Pienta K; Regine W; Ritter M; Rubin P; Safran H; Sauter E; Schell M; Stevens C; Trotti A; Vikram B;
Radiation Therapy Oncology Group. Research Plan 2002-2006. Translational Research Program.
International journal of radiation oncology, biology, physics 2001;51(3 Suppl 2):75-87.
-
2001: Sandler H; Shipley W U; Gomella L; Pienta K; Bard R H; Bruner D; Clark R; DeSilvio M; Gaspar L; Gillin M; Grignon D; Hammond E; Hanks G; Heydon K H; Kaufman D S; Lee W R; Michalski J; Mydlo J; Pisansky T; Pollack A; Porterfield H; Rifkin M; Roach M; Sanda M; True L; Vijayakumar S; Winter K A; Zeitman A;
Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee.
International journal of radiation oncology, biology, physics 2001;51(3 Suppl 2):28-38.
-
2000: Colletier P J; Ashoori F; Cowen D; Meyn R E; Tofilon P; Meistrich M E; Pollack A
Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.
International journal of radiation oncology, biology, physics 2000;48(5):1507-12.
-
2000: Pollack A; Zagars G K; Smith L G; Lee J J; von Eschenbach A C; Antolak J A; Starkschall G; Rosen I
Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3904-11.
-
2000: Cowen D; Salem N; Ashoori F; Meyn R; Meistrich M L; Roth J A; Pollack A
Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4402-8.
-
2000: Raut A; Huryn J; Pollack A; Zlotolow I
Unusual gingival presentation of post-transplantation lymphoproliferative disorder: a case report and review of the literature.
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2000;90(4):436-41.
-
2000: Storey M R; Pollack A; Zagars G; Smith L; Antolak J; Rosen I
Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial.
International journal of radiation oncology, biology, physics 2000;48(3):635-42.
-
2000: Chaney A W; Pollack A; McNeese M D; Zagars G K; Pisters P W; Pollock R E; Hunt K K
Primary treatment of cystosarcoma phyllodes of the breast.
Cancer 2000;89(7):1502-11.
-
2000: May C A; Tamaki K; Neumann R; Wilson G; Zagars G; Pollack A; Dubrova Y E; Jeffreys A J; Meistrich M L
Minisatellite mutation frequency in human sperm following radiotherapy.
Mutation research 2000;453(1):67-75.
-
2000: Pollack A; Smith L G; von Eschenbach A C
External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
International journal of radiation oncology, biology, physics 2000;48(2):507-12.
-
2000: White R A; Meistrich M L; Pollack A; Terry N H
Simultaneous estimation of T(G2+M), T(S), and T(pot) using single sample dynamic tumor data from bivariate DNA-thymidine analogue cytometry.
Cytometry 2000;41(1):1-8.
-
2000: Denny L; Kuhn L; Risi L; Richart R M; Pollack A; Lorincz A; Kostecki F; Wright T C
Two-stage cervical cancer screening: an alternative for resource-poor settings.
American journal of obstetrics and gynecology 2000;183(2):383-8.
-
2000: Bostwick D G; Grignon D J; Hammond M E; Amin M B; Cohen M; Crawford D; Gospadarowicz M; Kaplan R S; Miller D S; Montironi R; Pajak T F; Pollack A; Srigley J R; Yarbro J W
Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.
Archives of pathology & laboratory medicine 2000;124(7):995-1000.
-
2000: Perez C A; Beyer D C; Blasko J C; Forman J D; Hussey D H; Lee W R; Paryani S B; Pollack A; Potters L; Roach M; Scardino P; Schellhammer P; Leibel S
Definitive external beam irradiation in stage T1 and T2 carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
Radiology 2000;215 Suppl():1449-72.
-
2000: Roach M; Blasko J C; Perez C A; Beyer D C; Forman J D; Hussey D H; Lee W R; Paryani S B; Pollack A; Potters L; Scardino P; Schellhammer P; Leibel S
Treatment planning for clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
Radiology 2000;215 Suppl():1441-8.
-
2000: Perez C A; Beyer D C; Blasko J C; Forman J D; Hussey D H; Lee W R; Paryani S B; Pollack A; Potters L; Roach M; Scardino P; Schellhammer P; Leibel S
Postradical prostatectomy irradiation in carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
Radiology 2000;215 Suppl():1419-39.
-
2000: Lee W R; Pollack A; Perez C A; Beyer D C; Blasko J C; Forman J D; Hussey D H; Paryani S B; Potters L; Roach M; Scardino P; Schellhammer P; Leibel S
Node-positive prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
Radiology 2000;215 Suppl():1413-8.
-
2000: Pollack A; Paryani S B; Hussey D; Perez C A; Beyer D C; Blasko J C; Forman J D; Lee W R; Potters L; Roach M; Scardino P; Schellhammer P; Leibel S
Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
Radiology 2000;215 Suppl():1401-12.
-
2000: Potters L; Perez C A; Beyer D C; Blasko J C; Forman J D; Hussey D H; Lee W R; Paryani S B; Pollack A; Roach M; Scardino P; Schellhammer P; Leibel S
Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
Radiology 2000;215 Suppl():1383-400.
-
2000: Forman J D; Lee W R; Roach M; Perez C A; Beyer D C; Blasko J C; Hussey D H; Paryani S B; Pollack A; Potters L; Scardino P; Schellhammer P; Leibel S
Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
Radiology 2000;215 Suppl():1373-82.
-
2000: Kuhn L; Denny L; Pollack A; Lorincz A; Richart R M; Wright T C
Human papillomavirus DNA testing for cervical cancer screening in low-resource settings.
Journal of the National Cancer Institute 2000;92(10):818-25.
-
2000: Amato R J; Millikan R; Daliani D; Wood L; Logothetis C; Pollack A
Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):72-7.
-
2000: Pollack A; Ashoori F; Sikes C; Joon D L; von Eschenbach A C; Zagars G K; Meistrich M L
The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions.
International journal of radiation oncology, biology, physics 2000;46(1):153-8.
-
2000: Wright T C; Denny L; Kuhn L; Pollack A; Lorincz A
HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
JAMA : the journal of the American Medical Association 2000;283(1):81-6.
-
1999: Khoo V S; Pollack A; Cowen D; Joon D L; Patel N; Terry N H; Zagars G K; von Eschenbach A C; Meistrich M L; Troncoso P
Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy.
The Prostate 1999;41(3):166-72.
-
1999: Fleming J B; Berman R S; Cheng S C; Chen N P; Hunt K K; Feig B W; Respondek P M; Yasko A W; Pollack A; Patel S R; Burgess M A; Papadopoulos N E; Plager C; Zagars G; Benjamin R S; Pollock R E; Pisters P W
Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2772-80.
-
1999: Zagars G K; Pollack A; Smith L G
Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
International journal of radiation oncology, biology, physics 1999;44(4):809-19.
-
1999: Pollack A; Zagars G K; Rosen I I
Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity.
Seminars in oncology 1999;26(2):150-61.
-
1999: Liebross R H; Pollack A; Lankford S P; Zagars G K; von Eschenbach A C; Geara F B
Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome.
Cancer 1999;85(7):1577-85.
-
1999: Pollack A
What's your position? We have a need to know.
International journal of radiation oncology, biology, physics 1999;43(4):705-6.
-
1999: Ballo M T; Zagars G K; Pollack A; Pisters P W; Pollack R A
Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):158-67.
-
1999: Hanus M C; Zagars G K; Pollack A
Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation.
International journal of radiation oncology, biology, physics 1999;43(2):379-83.
-
1999: Pearlstone D B; Pisters P W; Bold R J; Feig B W; Hunt K K; Yasko A W; Patel S; Pollack A; Benjamin R S; Pollock R E
Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up.
Cancer 1999;85(1):85-92.
-
1998: Ballo M T; Zagars G K; Pollack A
Radiation therapy in the management of desmoid tumors.
International journal of radiation oncology, biology, physics 1998;42(5):1007-14.
-
1998: Antolak J A; Rosen I I; Childress C H; Zagars G K; Pollack A
Prostate target volume variations during a course of radiotherapy.
International journal of radiation oncology, biology, physics 1998;42(3):661-72.
-
1998: Pollack A; Zagars G K; Goswitz M S; Pollock R A; Feig B W; Pisters P W
Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation.
International journal of radiation oncology, biology, physics 1998;42(3):563-72.
-
1998: Zagars G K; Pollack A; Pettaway C A
Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation.
International journal of radiation oncology, biology, physics 1998;42(3):517-23.
-
1998: Liebross R H; Pollack A; Lankford S P; von Eschenbach A C; Zagars G K
Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy.
Urology 1998;52(4):647-52.
-
1998: Scher H; Bahnson R; Cohen S; Eisenberger M; Herr H; Kozlowski J; Lange P; Montie J; Pollack A; Raghaven D; Richie J; Shipley W
NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network.
Oncology (Williston Park, N.Y.) 1998;12(7A):225-71.
-
1998: Midis G P; Pollock R E; Chen N P; Feig B W; Murphy A; Pollack A; Pisters P W
Locally recurrent soft tissue sarcoma of the extremities.
Surgery 1998;123(6):666-71.
-
1998: Nguyen L N; Pollack A; Zagars G K
Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire.
Urology 1998;51(6):991-7.
-
1998: Pollack A; Zagars G K
Androgen ablation in addition to radiation therapy for prostate cancer: is there true benefit?
Seminars in radiation oncology 1998;8(2):95-106.
-
1998: Ballo M T; Zagars G K; Pisters P; Pollack A
The role of radiation therapy in the management of dermatofibrosarcoma protuberans.
International journal of radiation oncology, biology, physics 1998;40(4):823-7.
-
1998: Westney O L; Pisters L L; Pettaway C A; Tu S M; Pollack A; Dinney C P
Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder.
The Journal of urology 1998;159(3):792-5.
-
1998: Pollack A; Zagars G K
External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up?
Urology 1998;51(2):258-64.
-
1998: Chaney A W; Pollack A; McNeese M D; Zagars G K
Adjuvant radiotherapy for phyllodes tumor of breast.
Radiation oncology investigations 1998;6(6):264-7.
-
1997: Navone N M; Olive M; Ozen M; Davis R; Troncoso P; Tu S M; Johnston D; Pollack A; Pathak S; von Eschenbach A C; Logothetis C J
Establishment of two human prostate cancer cell lines derived from a single bone metastasis.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2493-500.
-
1997: Pisters P W; Patel S R; Varma D G; Cheng S C; Chen N P; Nguyen H T; Feig B W; Pollack A; Pollock R E; Benjamin R S
Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(12):3481-7.
-
1997: Pollack A; Zagars G K
External beam radiotherapy dose response of prostate cancer.
International journal of radiation oncology, biology, physics 1997;39(5):1011-8.
-
1997: Ciancio G; Viciana A; Pollack A; Joon D L; Wu C S; Ruiz P; Weppler D; Schiff E; Tzakis A
Flow cytometric DNA analysis of paraffin-embedded hepatocellular carcinoma from patients treated by orthotopic liver transplantation.
Transplantation proceedings 1997;29(7):2878-9.
-
1997: Pollack A; Wu C S; Czerniak B; Zagars G K; Benedict W F; McDonnell T J
Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1823-9.
-
1997: Pollack A; Czerniak B; Zagars G K; Hu S X; Wu C S; Dinney C P; Chyle V; Benedict W F
Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer.
International journal of radiation oncology, biology, physics 1997;39(3):687-95.
-
1997: Zagars G K; Pollack A
Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1997;44(3):213-21.
-
1997: Zagars G K; Pollack A
Serum testosterone levels after external beam radiation for clinically localized prostate cancer.
International journal of radiation oncology, biology, physics 1997;39(1):85-9.
-
1997: Zagars G K; Pollack A; von Eschenbach A C
Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation.
Cancer 1997;80(4):764-75.
-
1997: Joon D L; Hasegawa M; Sikes C; Khoo V S; Terry N H; Zagars G K; Meistrich M L; Pollack A
Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation.
International journal of radiation oncology, biology, physics 1997;38(5):1071-7.
-
1997: Pollack A; Joon D L; Wu C S; Sikes C; Hasegawa M; Terry N H; White R A; Zagars G K; Meistrich M L
Quiescence in R3327-G rat prostate tumors after androgen ablation.
Cancer research 1997;57(12):2493-500.
-
1997: Lankford S P; Pollack A; Zagars G K
Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
International journal of radiation oncology, biology, physics 1997;38(2):327-33.
-
1997: Pollack A; Troncoso P; Zagars G K; von Eschenbach A C; Mak A C; Wu C S; Terry N H
The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation.
The Prostate 1997;31(1):21-8.
-
1997: Zagars G K; Pollack A; von Eschenbach A C
Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
Cancer 1997;79(7):1370-80.
-
1997: Zagars G K; Pollack A; von Eschenbach A C
Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.
Urology 1997;49(3):327-34.
-
1997: Pollack A; Zagars G K; Cole C J; Dinney C P; Swanson D A; Grossman H B
Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy.
International journal of radiation oncology, biology, physics 1997;37(1):41-9.
-
1996: Zagars G K; Goswitz M S; Pollack A
Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy.
International journal of radiation oncology, biology, physics 1996;36(2):311-9.
-
1996: Pollack A; Zagars G Z
Radiotherapy for stage T3b transitional cell carcinoma of the bladder.
Seminars in urologic oncology 1996;14(2):86-95.
-
1996: Pollack A; Zagars G K
Radiotherapy vs. surgery for prostate cancer: an age old question.
International journal of radiation oncology, biology, physics 1996;35(2):407-9.
-
1996: Chyle V; Pollack A; Czerniak B; Stephens L C; Zagars G K; Terry N H; Meyn R E
Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer.
International journal of radiation oncology, biology, physics 1996;35(2):281-7.
-
1996: Pollack A; Lankford S; Zagars G K; Babaian R J
Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy.
Cancer 1996;77(8):1515-23.
-
1996: Wu C S; Pollack A; Czerniak B; Chyle V; Zagars G K; Dinney C P; Hu S X; Benedict W F
Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy.
Urology 1996;47(3):305-10.
-
1996: Zagars G K; Mullen J R; Pollack A
Malignant fibrous histiocytoma: outcome and prognostic factors following conservation surgery and radiotherapy.
International journal of radiation oncology, biology, physics 1996;34(5):983-94.
-
1996: Pollack A; Zagars G K; Starkschall G; Childress C H; Kopplin S; Boyer A L; Rosen I I
Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity.
International journal of radiation oncology, biology, physics 1996;34(3):555-64.
-
1995: Pollack A; Zagars G K; Cole C J; Dinney C P; Swanson D A; Grossman H B
The relationship of local control to distant metastasis in muscle invasive bladder cancer.
The Journal of urology 1995;154(6):2059-63; discussion 2063-4.
-
1995: Lankford S P; Pollack A; Zagars G K
Radiotherapy for regionally localized hormone refractory prostate cancer.
International journal of radiation oncology, biology, physics 1995;33(4):907-12.
-
1995: Zagars G K; Pollack A; von Eschenbach A C
Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
International journal of radiation oncology, biology, physics 1995;33(1):23-35.
-
1995: Cole C J; Pollack A; Zagars G K; Dinney C P; Swanson D A; von Eschenbach A C
Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone.
International journal of radiation oncology, biology, physics 1995;32(2):331-40.
-
1995: Pollack A; Terry N H; Wu C S; Wise B M; White R A; Meistrich M L
Specific staining of iododeoxyuridine and bromodeoxyuridine in tumors double labelled in vivo: a cell kinetic analysis.
Cytometry 1995;20(1):53-61.
-
1995: Zagars G K; Pollack A; Kavadi V S; von Eschenbach A C
Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
International journal of radiation oncology, biology, physics 1995;32(2):293-306.
-
1995: Zagars G K; Kavadi V S; Pollack A; von Eschenbach A C; Sands M E
The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?
International journal of radiation oncology, biology, physics 1995;32(1):21-32.
-
1995: Pollack A; Zagars G K; Kopplin S
Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer.
International journal of radiation oncology, biology, physics 1995;32(1):13-20.
-
1995: Hall M C; Navone N M; Troncoso P; Pollack A; Zagars G K; von Eschenbach A C; Conti C J; Chung L W
Frequency and characterization of p53 mutations in clinically localized prostate cancer.
Urology 1995;45(3):470-5.
-
1995: Zagars G K; Pollack A
Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Urology 1995;45(3):476-83.
-
1995: Pollack A; Zagars G K; Sands M E
Local treatment for prostate cancer: 90 years later--response to M. V. Pilepich.
International journal of radiation oncology, biology, physics 1995;31(2):436.
-
1995: Zagars G K; Ayala A G; von Eschenbach A C; Pollack A
The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.
International journal of radiation oncology, biology, physics 1995;31(2):237-45.
-
1995: Cutrone J A; Georgiou D; Khan S U; Pollack A; Laks M M; Brundage B H
Right ventricular mass measurement by electron beam computed tomography. Validation with autopsy data.
Investigative radiology 1995;30(1):64-8.
-
1995: Zagars G K; Pollack A; von Eschenbach A C; Ayala A G
Gleason grade and other prognostic factors--response to Drs. Hammond and Grignon.
International journal of radiation oncology, biology, physics 1995;31(2):435.
-
1995: Sands M E; Pollack A; Zagars G K
Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation.
International journal of radiation oncology, biology, physics 1995;31(1):13-9.
-
1994: Hall M C; Troncoso P; Pollack A; Zhau H Y; Zagars G K; Chung L W; von Eschenbach A C
Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy.
Urology 1994;44(6):869-75.
-
1994: Pollack A; Zagars G K; Dinney C P; Swanson D A; von Eschenbach A C
Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients.
Cancer 1994;74(10):2819-27.
-
1994: Pollack A; Zagars G K; el-Naggar A K; Terry N H
Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
Urology 1994;44(5):711-8.
-
1994: Pollack A; Zagars G K; Swanson D A
Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors.
International journal of radiation oncology, biology, physics 1994;30(2):267-77.
-
1994: Geara F B; Zagars G K; Pollack A
Influence of initial presentation on treatment outcome of clinically localized prostate cancer treated by definitive radiation therapy.
International journal of radiation oncology, biology, physics 1994;30(2):331-7.
-
1994: Kavadi V S; Zagars G K; Pollack A
Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.
International journal of radiation oncology, biology, physics 1994;30(2):279-87.
-
1994: Sands M E; Zagars G K; Pollack A; von Eschenbach A C
Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer.
Urology 1994;44(2):215-20.
-
1994: Pollack A; Zagars G K; Kavadi V S
Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Cancer 1994;74(2):670-8.
-
1994: Park H S; Shin D M; Lee J S; Komaki R; Pollack A; Putnam J B; Cox J D; Hong W K
Thymoma. A retrospective study of 87 cases.
Cancer 1994;73(10):2491-8.
-
1994: Zagars G K; Sands M E; Pollack A; von Eschenbach A C
Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome.
The Journal of urology 1994;151(5):1330-3.
-
1994: White R A; Pollack A; Terry N H
Simultaneous cytokinetic measurement of aneuploid tumors and associated diploid cells following continuous labelling with chlorodeoxyuridine.
Cytometry 1994;15(4):311-9.
-
1994: Zagars G K; Geara F B; Pollack A; von Eschenbach A C
The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy.
Cancer 1994;73(7):1904-12.
-
1994: Pollack A; Zagars G K; el-Naggar A K; Gauwitz M D; Terry N H
Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy.
Cancer 1994;73(7):1895-903.
-
1994: White R A; Pollack A; Terry N H; Meistrich M L; Cao S
Double labelling to obtain S phase subpopulations: application to determine cell kinetics of diploid cells in an aneuploid tumour.
Cell proliferation 1994;27(3):123-37.
-
1994: Gauwitz M D; Pollack A; el-Naggar A K; Terry N H; von Eschenbach A C; Zagars G K
The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy.
International journal of radiation oncology, biology, physics 1994;28(4):821-8.
-
1994: Pollack A; Terry N H; White R A; Cao S; Meistrich M L; Milas L
Proliferation kinetics of recruited cells in a mouse mammary carcinoma.
Cancer research 1994;54(3):811-7.
-
1994: Zagars G K; Pollack A
The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1994;30(2):121-7.
-
1994: Zhau H E; Pisters L L; Hall M C; Zhao L S; Troncoso P; Pollack A; Chung L W
Biomarkers associated with prostate cancer progression.
Journal of cellular biochemistry. Supplement 1994;19():208-16.
-
1993: Pollack A; White R A; Cao S; Meistrich M L; Terry N H
Calculating potential doubling time using monoclonal antibodies specific for two halogenated thymidine analogues.
International journal of radiation oncology, biology, physics 1993;27(5):1131-9.
-
1993: Zagars G K; Pollack A
The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer.
Cancer 1993;72(3):832-42.
-
1993: Ciancio G; Pollack A; Block N L
Flow cytometric analysis of DNA and nuclear protein in paraffin-embedded tissue.
Cytometry 1993;14(2):205-9.
-
1993: Pollack A; Terry N H; Van N T; Meistrich M L
Flow cytometric analysis of two incorporated halogenated thymidine analogues and DNA in a mouse mammary tumor grown in vivo.
Cytometry 1993;14(2):168-72.
-
1993: Pollack A; Ciancio G; Terry N H; Block N L
Recognition and reduction of artifacts from autolysis in paraffin-embedded tissue using DNA/nuclear protein flow cytometry.
Cytometry 1993;14(5):565-8.
-
1992: Pollack A; Lask P; Kassner E G; Wood B P
Radiological case of the month. Retrocardiac pneumomediastinum.
American journal of diseases of children (1960) 1992;146(7):831-2.
-
1992: Pollack A; el-Naggar A K; Cox J D; Ro J Y; Sahin A; Komaki R
Thymoma. The prognostic significance of flow cytometric DNA analysis.
Cancer 1992;69(7):1702-9.
-
1992: Pollack A; Komaki R; Cox J D; Ro J Y; Oswald M J; Shin D M; Putnam J B
Thymoma: treatment and prognosis.
International journal of radiation oncology, biology, physics 1992;23(5):1037-43.
-
1992: Aroeti B; Casanova J; Okamoto C; Cardone M; Pollack A; Tang K; Mostov K
Polymeric immunoglobulin receptor.
International review of cytology 1992;137B():157-68.
-
1991: Wolloch E H; Sevin B U; Perras J P; Gottlieb C F; Pollack A; Ramos R; Schiano M A; Averette H E
Cell kinetic perturbations after irradiation and caffeine in the BG-1 ovarian carcinoma cell line.
Gynecologic oncology 1991;43(1):29-36.
-
1990: Grobman L R; Fisch U; Pollack A
Central neurofibromatosis: a clinical-pathological correlation.
The American journal of otology 1990;11(2):108-12.
-
1990: Pollack A; Ciancio G
Cell cycle phase-specific analysis of cell viability using Hoechst 33342 and propidium iodide after ethanol preservation.
Methods in cell biology 1990;33():19-24.
-
1990: Pollack A
Flow cytometric cell-kinetic analysis by simultaneously staining nuclei with propidium iodide and fluorescein isothiocyanate.
Methods in cell biology 1990;33():315-23.
-
1988: Ciancio G; Pollack A; Taupier M A; Block N L; Irvin G L
Measurement of cell-cycle phase-specific cell death using Hoechst 33342 and propidium iodide: preservation by ethanol fixation.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1988;36(9):1147-52.
-
1987: Sevin B U; Pollack A; Averette H E; Ramos R; Donato D
In vivo cell kinetic effects of cis-platinum on human ovarian cancer xenografts measured by dual parameter flow cytometry.
Cytometry 1987;8(2):153-62.
-
1986: Sevin B U; Pollack A; Averette H E; Ramos R; Greening S E; Evans D
In vivo chemosensitivity testing in patients with gynecologic malignancies and nude mouse xenografts by monitoring cell kinetic parameters and DNA distribution patterns: a preliminary report.
Gynecologic oncology 1986;24(1):27-40.
-
1986: Pollack A; Moulis H; Prudhomme D L; Block N L; Irvin G L
Flow cytometric analysis of cell kinetic responses using measurements of correlated DNA and nuclear protein.
Annals of the New York Academy of Sciences 1986;468():55-66.
-
1985: Pollack A; Moulis H; Greenstein D B; Block N L; Irvin G L
Cell kinetic effects of incorporated 3H-thymidine on proliferating human lymphocytes: flow cytometric analysis using the DNA/nuclear protein method.
Cytometry 1985;6(5):428-36.
-
1985: Pollack A; Block N L; Stover B J; Irvin G L
Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation.
Cancer research 1985;45(3):1052-7.
-
1984: Pollack A; Moulis H; Block N L; Irvin G L
Quantitation of cell kinetic responses using simultaneous flow cytometric measurements of DNA and nuclear protein.
Cytometry 1984;5(5):473-81.
-
1984: Pollack A; Block N L; Stover B J; Fuentes M P; Irvin G L
Effects of the gonadotropin-releasing hormone agonist [D-leu6, desgly-NH2(10), proethylamide9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth.
The Journal of urology 1984;131(2):399-403.
-
1983: Pollack A; Block N L; Stover B J; Irvin G L; Fuentes M P; Claflin A J; Malinin T I
In vivo selection of androgen-insensitive cells in R3327-G rat prostate tumors: diethylstilbestrol diphosphate treatment versus orchiectomy.
Journal of the National Cancer Institute 1983;70(5):907-14.
-
1982: Claflin A J; Pollack A; Malinin T; Block N L; Irvin G L
Flow cytometric analysis of R3327 rat prostate adenocarcinoma grown in vivo and in vitro.
Journal of the National Cancer Institute 1982;69(1):79-87.
-
1982: Pollack A; Prudhomme D L; Greenstein D B; Irvin G L; Claflin A J; Block N L
Flow cytometric analysis of RNA content in different cell populations using pyronin Y and methyl green.
Cytometry 1982;3(1):28-35.
-
1982: Pollack A; Irvin G L; Block N L; Lipton R M; Stover B J; Claflin A J
Hormone sensitivity of the R3327-G rat prostate adenocarcinoma: growth rate, DNA content, and hormone receptors.
Cancer research 1982;42(6):2184-90.
-
1981: Collins J M; Bagwell C B; Block N L; Claflin A J; Irvin G L; Pollack A; Stover B
Flow cytometric monitoring of R 3327 rat prostate carcinoma.
Investigative urology 1981;19(1):8-13.
-
1981: Pollack A; Bagwell C B; Block N L; Irvin G L; Claflin A J; Stover B J
Flow cytometric analysis of the response of the R3327-G rat prostatic adenocarcinoma to endocrine manipulation.
Journal of surgical oncology 1981;18(4):389-98.
-
1980: Pollack A; Bagwell C B; Irvin G L; Jensen J A
The kinetics of the formation of a G2 block from tritiated thymidine in phytohemagglutinin-stimulated human lymphocytes.
Cytometry 1980;1(1):57-64.
-
1979: Pollack A; Bagwell C B; Irvin G L
Radiation from tritiated thymidine perturbs the cell cycle progression of stimulated lymphocytes.
Science (New York, N.Y.) 1979;203(4384):1025-7.
-
1979: Pollack A; Bagwell C B; Hudson J L; Irvin G L
Differences in flow cytometry and 3H-thymidine analyses of perturbed human lymphocytes.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1979;27(1):486-90.
-
1977: Panksepp J; Pollack A; Meeker R B; Sullivan A C
(-)-Hydroxycitrate and conditioned aversions.
Pharmacology, biochemistry, and behavior 1977;6(6):683-7.
-
1976: Gratzner H G; Pollack A; Ingram D J; Leif R C
Deoxyribonucleic acid replication in single cells and chromosomes by immunologic techniques.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1976;24(1):34-9.
Sign-in to see more